Kelsey Goodwin
Stock Analyst at Guggenheim
(0)
# 4474
Out of 5,245 analysts
15
Total ratings
33.33%
Success rate
-12.48%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Genelux | Initiates Coverage On: Buy | 8 | 2.44 | 227.87% | 1 | Oct 29, 2024 | |
Nuvalent | Maintains: Strong Buy | 99 105 | 75.88 | 38.38% | 2 | Sep 16, 2024 | |
UroGen Pharma | Initiates Coverage On: Buy | 40 | 10.26 | 289.86% | 1 | Aug 22, 2024 | |
Macrogenics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 31, 2024 | |
2seventy bio | Downgrades: Neutral | n/a | n/a | n/a | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 15 | 0.91 | 1548.35% | 1 | Oct 31, 2022 |